IPF Patients and Doctors Looking for New Treatment Options

IPF Patients and Doctors Looking for New Treatment Options

pf_ipf doctors

Spherix Global Insights, GmbH, a business intelligence and market research company based in Switzerland, recently reported a study revealing that idiopathic pulmonary fibrosis (IPF) remains a challenge in terms of treatment, especially since the majority of patients are diagnosed at already advanced disease stages. The Spherix study is entitled “Market Dynamix: Idiopathic Pulmonary Fibrosis (IPF).”

Currently, there are two approved drugs for IPF treatment: Esbriet (pirfenidone), developed by Roche, and Ofev (nintedanib), developed by Boehringer Ingelheim. Several companies are exploring potential new therapies, including MediciNova (tipelukast), Biogen (STX-100), Gilead (simtuzumab), Afferent (AF-219), and FibroGen (FG-3019). However, according to a Spherix press release, physicians are not well-informed concerning future therapeutic options for IPF and the potential benefits they may offer.

Read more about it: http://bit.ly/22MCruQ

Leave a Comment

Your email address will not be published. Required fields are marked *